Loading
Hemogenyx Pharmaceuticals is developing a CAR-T cell therapy, a patient's own immune cells engineered to attack cancer, aimed at the FLT3 protein on acute myeloid leukaemia cells. It is in a first trial at MD Anderson for leukaemia that has come back or stopped responding.
Hemogenyx Pharmaceuticals plc is listed on the London Stock Exchange (HEMO) and headquartered at 6 Heddon Street, London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, at a research facility on Amsterdam Avenue, New York. The company was incorporated in England and Wales on 13 February 2013 and admitted to the LSE on 5 October 2017, according to the company. HG-CT-1 (HEMO-CAR-T) is an autologous third-generation CAR-T using a proprietary humanised anti-FLT3 scFv that the company says does not compete with FLT3 ligand; a phase 1 study in relapsed or refractory AML at MD Anderson Cancer Center is registered (NCT06786533), and the company's pipeline page reported two patients dosed and a third recruited. A preclinical FLT3 x CD3 bispecific antibody (CDX) is also in development, with stated potential for bone marrow transplant conditioning. Its first registered cancer trial, NCT06786533, was posted on ClinicalTrials.gov in January 2025.
Shares FLT3, CD3, Bispecific antibodies, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares CD3, Acute myeloid leukaemia.
Shares CD3, Bispecific antibodies.
Shares CD3, Bispecific antibodies.
Shares FLT3, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/